Form4insider filings, from the source

SEC Form 4 · accession 0001209191-19-017840

REATA PHARMACEUTICALS INC · RETA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Michael D Wortley
Officer — Chief Legal Officer
Period of report
Mar 5, 2019
Accepted (ET)
Mar 7, 2019 · 5:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358762

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Class A common stockF1Mar 5, 2019C26,940—A26,940D
Class A common stockF2Mar 5, 2019S8,489$98.6029D18,451D
Class A common stockF3Mar 5, 2019S7,019$99.4756D11,432D
Class A common stockF4Mar 5, 2019S5,041$100.425D6,391D
Class A common stockF5Mar 5, 2019S300$101.6917D6,091D
Class A common stockF6Mar 5, 2019S4,161$102.508D1,930D
Class A common stockF7Mar 5, 2019S1,830$103.5419D100D
Class A common stockMar 5, 2019S100$104.145D0D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Employee Stock Option (right to buy)F8,F1$11.00Mar 5, 2019M26,940D—May 25, 2026Class B common stock26,94012,245D
Class B common stockF1—Mar 5, 2019M26,940A——Class A common stock26,94026,940D
Class B common stockF1—Mar 5, 2019C26,940D——Class A common stock26,9400D

Explanation of responses